SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. You have free access to this content1
    Filippo Montemurro, Maurizio Scaltriti, Biomarkers of drugs targeting HER-family signalling in cancer, The Journal of Pathology, 2014, 232, 2
  2. 2
    Laura Orlando, Francesco Giotta, Vito Lorusso, Ferdinando De Vita, Gianfranco Filippelli, Evaristo Maiello, Ferdinando Riccardi, Giovanni Luigi Pappagallo, Palma Fedele, Nicola Gebbia, Francesco Verderame, Sandro Barni, Livio Blasi, Salvatore Pisconti, Giuseppe Colucci, Saverio Cinieri, Biweekly combination of trastuzumab, docetaxel and gemcitabine for HER2-positive metastatic breast cancer: results of a Phase II GOIM study, Future Oncology, 2014, 10, 5, 725

    CrossRef

  3. 3
    Arjun Mehta, Debu Tripathy, Co-targeting estrogen receptor and HER2 pathways in breast cancer, The Breast, 2014, 23, 1, 2

    CrossRef

  4. 4
    Amelia B. Zelnak, Petros Nikolinakos, Jayanthi Srinivasiah, William Jonas, Andrew Pippas, Yuan Liu, Xiaoxian Li, Mylin Torres, Ruth M. O'Regan, High Pathologic Complete Response in Her2-Positive, Early-Stage Breast Cancer to a Novel Nonanthracycline Neoadjuvant Chemotherapy, Clinical Breast Cancer, 2014,

    CrossRef

  5. 5
    Filippo Montemurro, Aleix Prat, Valentina Rossi, Giorgio Valabrega, Jeff Sperinde, Caterina Peraldo-Neia, Michela Donadio, Patricia Galván, Anna Sapino, Massimo Aglietta, José Baselga, Maurizio Scaltriti, Potential biomarkers of long-term benefit from single-agent trastuzumab or lapatinib in HER2-positive metastatic breast cancer, Molecular Oncology, 2014, 8, 1, 20

    CrossRef

  6. 6
    O. Brouckaert, R. Paridaens, G. Floris, E. Rakha, K. Osborne, P. Neven, A critical review why assessment of steroid hormone receptors in breast cancer should be quantitative, Annals of Oncology, 2013, 24, 1, 46

    CrossRef

  7. 7
    Naoki Hayashi, Naoki Niikura, Hideko Yamauchi, Seigo Nakamura, Naoto T. Ueno, Adding hormonal therapy to chemotherapy and trastuzumab improves prognosis in patients with hormone receptor-positive and human epidermal growth factor receptor 2-positive primary breast cancer, Breast Cancer Research and Treatment, 2013, 137, 2, 523

    CrossRef

  8. 8
    Filippo Montemurro, Massimo Aglietta, Duration of trastuzumab for HER2-positive breast cancer, The Lancet Oncology, 2013, 14, 8, 678

    CrossRef

  9. 9
    F. Montemurro, S. Di Cosimo, G. Arpino, Human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor-positive breast cancer: new insights into molecular interactions and clinical implications, Annals of Oncology, 2013, 24, 11, 2715

    CrossRef

  10. 10
    Pradip De, Max Hasmann, Brian Leyland-Jones, Molecular determinants of trastuzumab efficacy: What is their clinical relevance?, Cancer Treatment Reviews, 2013, 39, 8, 925

    CrossRef

  11. 11
    Lale Kostakoglu, Radionuclide Response Assessment of Breast Cancer, Seminars in Nuclear Medicine, 2013, 43, 4, 299

    CrossRef

  12. 12
    Paola Ferrari, Andrea Nicolini, Angelo Carpi, Targeted therapies of metastatic breast cancer: Relationships with cancer stem cells, Biomedicine & Pharmacotherapy, 2013, 67, 6, 543

    CrossRef

  13. 13
    Filippo Montemurro, Valentina Rossi, Elena Geuna, Giorgio Valabrega, Rossella Martinello, Andrea Milani, Massimo Aglietta, Current status and future perspectives in the endocrine treatment of postmenopausal, hormone receptor-positive metastatic breast cancer, Expert Opinion on Pharmacotherapy, 2012, 13, 15, 2143

    CrossRef

  14. 14
    Michelle M. Kim, Shaheenah Dawood, Pamela Allen, Aysegul A. Sahin, Wendy A. Woodward, Benjamin D. Smith, Eric A. Strom, Kelly K. Hunt, Funda Meric-Bernstam, Ana Maria Gonzalez-Angulo, Thomas A. Buchholz, Hormone receptor status influences the locoregional benefit of trastuzumab in patients with nonmetastatic breast cancer, Cancer, 2012, 118, 20
  15. 15
    PierFranco Conte, Valentina Guarneri, The Next Generation of Biologic Agents: Therapeutic Role in Relation to Existing Therapies in Metastatic Breast Cancer, Clinical Breast Cancer, 2012, 12, 3, 157

    CrossRef

  16. 16
    Rita Nahta, Ruth M. O’Regan, Therapeutic implications of estrogen receptor signaling in HER2-positive breast cancers, Breast Cancer Research and Treatment, 2012, 135, 1, 39

    CrossRef

  17. 17
    Lucia Del Mastro, Matteo Lambertini, Claudia Bighin, Alessia Levaggi, Alessia D’Alonzo, Sara Giraudi, Paolo Pronzato, Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patients, Expert Review of Anticancer Therapy, 2012, 12, 11, 1391

    CrossRef